Vancouver, British Columbia – (October 16, 2017) – True Leaf Medicine International Ltd. (“True Leaf”) (CSE: MJ) (FSE: TLA) (OTCQB: TRLFF), a company involved in the hemp and cannabis-based product industry, has secured DTC eligibility for its common shares from The Depository Trust Company (DTC) effective October 10, 2017.

The DTC is a subsidiary of the Depository Trust & Clearing Corporation (DTCC), and manages the electronic clearing and settlement for the vast majority of publicly traded equities and other securities in the United States. Securities that are eligible to be electronically cleared and settled through DTC are considered “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.

"We are pleased to announce that we have obtained DTC eligibility,” commented True Leaf CEO Darcy Bomford. “Electronic trading is the standard in today´s financial markets, and becoming DTC eligible simplifies the process of trading and exchanging our common shares. We continue to make positive steps to grow True Leaf, and we would like to thank our agent, VStock Transfer, for its guidance through this process,” he added. “We will continue to update our shareholders on our progress."

About True Leaf

True Leaf Medicine International Ltd., through its wholly owned subsidiary ‘True Leaf Pet’, has entered the global pet industry, forecast to reach $117 billion US in 2021, with a line of hemp-focused pet supplements in Canada, the United States and Europe. The company has also filed an application under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) to become a Canadian licensed producer of medical cannabis through its ‘True Leaf Medicine’ subsidiary. It has passed through the preliminary and enhanced screening process of Health Canada’s review and has recently received approval to build its facility.

Forward-Looking Information:

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements.  Although True Leaf believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties.  These statements speak only as of the date of this press release.  Actual results could differ materially from those currently anticipated due to a number of factors and risks discussed in True Leaf’s continuous disclosure filings available under the Company´s profile on  While the Company may elect to, it does not undertake to update this information at any particular time.
Media Contact:
Paul Sullivan
Director, Public Relations
O: 604-685-4742
M: 604-603-7358
Investor Contact:
Kevin Bottomley
Director and Corporate Relations
M: 778-389-9933


Live Chart CSE:MJ




Write a comment

Likes | 1
Dislikes | 0
Name: True Leaf Medicine International Ltd.
Canada Symbol: MJ
Germany Symbol / WKN: TLA / A14NM1
Shares Issued & Outstanding: 69,845,287
Phone: +1 778-389-9933

Anmeldung zum Newsletter:

Newsletter deutsch:
Newsletter englisch:
Sie erhalten nach der Anmeldung eine E-Mail mit einem Bestätigungslink. Erst nach Erfolgreicher Bestätigung sind Sie für den Newsletter angemeldet.


english/german - german/english